You are a helpful, respectful, and honest assistant. Always answer as helpfully as possible, while being safe. Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content. Please ensure that your responses are socially unbiased and positive in nature. If a question does not make any sense or is not factually coherent, explain why instead of answering something not correct. If you don't know the answer to a question, please don't share false information.
What is True about BCR-ABL 'trials' are all except: and explain in detail?
BCR- ABL fusion is responsible for form action of Tyrosine kinase enzyme. Variant of Tyrosine kinase:- (1) 190 k Da:- seen in B-ALL (2) 210 KDa:- seen in CML (3) 230 KDa:- seen in CNL (chronic neutrophilic leukemia ) Aggressiveness of cancer based on size of Tyrosine kinase :- 190 >>>210>>230 KDa. 190 KDa seen in B-ALL :- most aggressive course B-ALL with translocation (9:22) has bad prognosis 230 KDa :- least aggressive course (indolent course)